Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Enfuvirtide Fuzeon
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Abacavir Ziagen
Abacavir-Lamivudine Epzicom
Abacavir-Lamivudine-Zidovudine Trizivir
Didanosine Videx
Emtricitabine Emtriva
Lamivudine Epivir
Stavudine Zerit
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF Viread
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Zidovudine Retrovir
Zidovudine-Lamivudine Combivir
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Nevirapine Viramune
Rilpivirine Edurant
Atazanavir Reyataz
Atazanavir-Cobicistat Evotaz
Darunavir Prezista
Darunavir-Cobicistat Prezcobix
Fosamprenavir Lexiva
Indinavir Crixivan
Lopinavir-Ritonavir Kaletra
Nelfinavir Viracept
Saquinavir Invirase
Tipranavir Aptivus
Cobicistat Tybost
Ritonavir NorvirSection Navigation
Section Navigation
Prevention of HIV Overview3rd Edition
Module Core Competency
Apply Evidence-Based Recommendations for the Prevention of HIV Transmission
Target Audience
The Prevention of HIV module emphasizes new prevention strategies both for persons with HIV infection and for persons not infected with HIV. This module also addresses occupational and nonoccupational HIV postexposure prophylaxis.
Herausgeber
David H. Spach, MD
David H. Spach, MD
Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
Disclosures: None
Free CNE/CME
Available in the
Module Lessons
1Lesson 1 Preventing Perinatal HIV Transmission
- Learning Objectives
- Explain the mechanisms of perinatal HIV transmission and interventions to reduce the risks of perinatal HIV transmission
- List preferred initial antiretroviral regimens for pregnant people with HIV
- Discuss indications for use of intravenous zidovudine and cesarean section for pregnant people with HIV
- Describe recommended antiretroviral prophylaxis for infants born to pregnant people with HIV
- Summarize recommendations for initial management of infants exposed to HIV, including HIV diagnostic testing and monitoring
- Quick ReferencePreventing Perinatal HIV Transmission Core Concepts
2Lesson 2 Preventing HIV Transmission in Persons with HIV
- Learning Objectives
- Explain the concept of HIV treatment as prevention
- Summarize key studies that demonstrate the benefit of antiretroviral therapy in preventing HIV transmission
- Describe the interplay of HIV status awareness, HIV RNA suppression, and HIV transmission
- Highlight evidence-based behavioral and structural strategies to reduce HIV transmission
- Identify major biomedical strategies to reduce transmission of HIV
- Quick ReferencePreventing HIV Transmission in Persons with HIV Core Concepts
- Introduction and Background
- Antiretroviral Treatment as Prevention
- Knowledge of HIV Status
- Behavioral Prevention Interventions for Persons with HIV
- Importance of Diagnosing and Treating Acute HIV Infection
- Screening and Treatment of Sexually Transmitted Infections
- Circumcision
- Prevention Strategies in Persons with Substance Use
- Summary Points
3Lesson 3 Occupational Postexposure Prophylaxis
- Learning Objectives
- Discuss risk for occupational acquisition of HIV with a needlestick injury
- State the rationale for using occupational HIV postexposure prophylaxis (PEP)
- Describe current indications for the use of occupational HIV PEP, including strategies for risk assessment following an occupational exposure
- Summarize recommended antiretroviral therapy regimens and duration of therapy for occupational HIV PEP
- List recommended clinical and laboratory monitoring following occupational exposure to HIV
- Quick ReferenceOccupational Postexposure Prophylaxis Core Concepts
- Einführung
- Rationale for Occupational HIV PEP
- Risk Assessment of the Occupational Exposure Event
- Recommended Initial Steps Following An Exposure Event
- Recommended Antiretroviral Regimens for Occupational HIV PEP
- Obtaining Expert Consultation for Occupational HIV PEP
- Baseline Evaluation and Counseling for Health Care Worker
- Follow-Up of Health Care Worker After Exposure Event
- Summary Points
4Lesson 4 Nonoccupational Postexposure Prophylaxis
- Learning Objectives
- Describe indications for the use of nonoccupational postexposure prophylaxis (PEP)
- Summarize appropriate antiretroviral therapy regimens and duration of therapy for nonoccupational PEP
- List recommended clinical and laboratory monitoring following nonoccupational exposure to HIV
- Identify appropriate candidates for transition from nonoccupational PEP to HIV preexposure prophylaxis (PrEP)
- Discuss indications for obtaining expert consultation for nonoccupational PEP
- Quick ReferenceNonoccupational Postexposure Prophylaxis Core Concepts
- Introduction and Background
- Rationale for Providing Nonoccupational HIV PEP
- Evaluation for Nonoccupational HIV PEP
- Indications for Initiating Nonoccupational HIV PEP
- Recommended Therapy for Nonoccupational HIV PEP
- Expert Consultation for Nonoccupational HIV PEP
- Laboratory Testing for Source and Exposed Persons
- Nonoccupational HIV PEP in Special Populations and Circumstances
- Initial Medication Prescription and Follow-up after Evaluation
- Transitioning from Nonoccupational HIV PEP to HIV PrEP
- Concerns with Nonoccupational Postexposure Prophylaxis
- Summary Points
5Lesson 5 HIV Preexposure Prophylaxis (PrEP)
- Learning Objectives
- List persons to consider who may benefit from HIV PrEP
- Explain recommendations for testing and counseling prior to starting PrEP
- Discuss the recommended PrEP regimens, including dosing, safety, efficacy, and clinical eligibility
- Describe recommended clinical and laboratory baseline evaluation and monitoring for persons receiving HIV PrEP
- Summarize initial management of persons who develop HIV while receiving HIV PrEP
- Quick ReferenceHIV Preexposure Prophylaxis (PrEP) Core Concepts
- Einführung
- Persons to Consider for HIV PrEP
- Recommended Regimens and Dosing for HIV PrEP
- Baseline Laboratory Evaluation, Immunizations, and Counseling
- Major HIV PrEP Studies
- Time to Achieve Protection after Initiating HIV PrEP
- Impact of Adherence on Efficacy of HIV PrEP
- Laboratory Monitoring on HIV PrEP
- Acquisition of HIV in the Setting of HIV PrEP
- HIV PrEP and Development of HIV Drug Resistance
- Adverse Effects of Medications Used for HIV PrEP
- Changes in Sexual Practices Among Persons Receiving HIV PrEP
- Discontinuing PrEP
- Transitioning from Nonoccupational HIV PEP to HIV PrEP
- Disparities in HIV PrEP Use
- Future HIV PrEP Medications
- Summary Points
Share by e-mail
Check
-On-
Learning
Questions
-On-
Learning
Questions
The Check-on-Learning Questions are short and topic related. They are meant to help you stay on track throughout each lesson and check your understanding of key concepts.